AirWatch™ Named an Innovator in Independent Research Firm’s Market Overviews for Cloud-Hosted MDM Solutions and Managed Services and On-Premise MDM Solutions
Flexible architecture; user-friendly, actionable management dashboard; competitive, transparent pricing; advanced reporting; sophisticated security features; and strong application management continue to serve as key differentiators for AirWatch
AirWatch™, the global leader and innovator in mobile security, mobile device management (MDM) and mobile application management (MAM), today announced that it has been named an “innovator” in the Forrester Research, Inc. Market Overviews: Cloud-Hosted MDM Solutions and Managed Services and On-premise MDM Solutions. AirWatch was one of only two vendors recognized as an innovator in the Cloud-Hosted MDM report, and one of just four in the On-premise report out of a marketplace of 40 vendors offering these solutions.
Forrester Research interviewed 24 vendor companies and 184 user companies on the following key criteria: configuration, reporting, and support; mobile security management, including PIN enforcement, data wipes, jailbreak or root detection encryption and data leak prevention; software distribution, white and blacklist capabilities and enterprise app stores; and differentiating criteria, including platform support, integration and availability. Forrester Research segmented the MDM vendor landscape into four distinct groups in its Market Overview for Cloud-Hosted MDM: innovators, new entrants, best-of-breed and services, and divided the On-premise MDM vendor landscape into three distinct groups: innovators, incumbents and best-of-breed.
The Forrester Research Market Overviews on Cloud-Hosted MDM Solutions and Managed Services and On-premise MDM Solutions state, “Although many vendors offer hosted infrastructure solutions, AirWatch supports flexible architectures in that it can be delivered through an on-premise solution, an appliance, or a SaaS solution. AirWatch’s user-friendly, actionable management dashboard and competitive pricing have made it a top MDM contender for many firms¹. AirWatch also boasts strong on-premise and WLAN management solutions².”
“We believe that being recognized as an innovator by Forrester Research further validates and reinforces our goal to simplify mobility by providing enterprises with a comprehensive, leading mobile security and management solution,” said John Marshall, CEO, AirWatch. “Built on a true, multi-tenant architecture, AirWatch is highly scalable, enabling companies to easily move from pilot programs to large device deployments. When a company selects AirWatch, they receive both the best product and best price point.”
The AirWatch solution provides a full set of mobile security, MDM and MAM features, including the most accessible, easy-to-use web- and mobile-based management console; a Secure Content Locker; a Secure Email Gateway; an AirWatch App Catalog; the ability to securely manage both corporate- and employee-liable devices and location-based services. AirWatch’s API integration capabilities include the ability to integrate key enterprise platforms such as LDAP directory servers, Microsoft Active Directory, Microsoft Exchange, Microsoft BPOS-D, Microsoft Office 365, IBM Lotus Notes and Google Gmail for Business, as well as Public Key Infrastructures (PKI) and certificate management frameworks, streamlining the generation and management of certificates used on mobile devices for authentication and encryption.
AirWatch also provides enterprises with advanced reporting, including an extensive library of high-level and detailed device reports. IT administrators can leverage these pre-defined reports or create custom reports based on specific devices, user groups, date ranges or file preferences.
A privately-held company, AirWatch empowers organizations across a wide variety of industries to deploy, secure, track and manage all of their mobile assets. With AirWatch, corporate IT departments can streamline and automate the management and support of all corporate and employee-liable mobile devices; reduce the cost and effort of device deployments; and increase IT efficiencies and response times.
For more information about the Forrester Research Market Overviews download the reports:
- Market Overview: Cloud-Hosted Mobile Device Management Solutions And Managed Services
- Market Overview: On-Premises Mobile Device Management Solutions, Q3 2011
¹-“Market Overview: Cloud-Hosted Mobile Device Management Solutions And Managed Services”, Forrester Research, January 3, 2012
²-“Market Overview: On-Premises Mobile Device Management Solutions, Q3 2011”, Forrester Research, January 3, 2012
About AirWatch
AirWatch is the global leader and innovator of enterprise-grade smartphone security and mobile device management solutions. Positioned in the Leaders quadrant of Gartner, Inc.’s Magic Quadrant for Mobile Device Management Software 2011, AirWatch helps to deploy, secure, track and manage an enterprise’s entire fleet of Android, Apple’s iOS, BlackBerry, Windows Mobile, Windows 7 and Symbian devices. In October 2011, Info-Tech Research Group listed AirWatch as a “Champion” in the firm’s Mobile Device Management Vendor Landscape and also listed it as the “best bang for your buck” through its Value Score, which indexes each product offering and business strength relative to their price point.
AirWatch offers the industry’s most scalable and flexible deployment options with Software as a Service (SaaS), appliance or on premise solutions. SaaS pricing starts at a $3 per month subscription per device. Appliance pricing starts at a one-time fee of $6,500 for the hardware and includes a one-year warranty. On premise pricing starts at a one-time fee of $40 per device.
An award-winning company, AirWatch recently won several categories in the 2011 Mobile Star Awards. AirWatch has more than 1,500 customers in the retail, financial services, healthcare, government, distribution, education, hospitality, manufacturing, telecommunications and transportation industries. For more information, visit www.air‐watch.com .
© 2012 AirWatch LLC. All rights reserved. AirWatch™ and the AirWatch logo are trademarks of AirWatch, LLC. Android is a trademark of Google Inc. Apple and iOS are trademarks of Apple Inc. Blackberry is a trademark of Research In Motion Limited. Symbian is a trademark of Nokia. Windows Mobile and Windows 7 are trademarks of Microsoft. All other brands and trademarks mentioned in this press release are the property of their respective owners.
Contact:
AirWatch
Nichole Bigley, 404-395-8810
nicholebigley@air-watch.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom